Geumhee Gwak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Geumhee Gwak has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Hyunjin Cho
Department of Surgery, College of Medicine, Sanggye Paik Hospital, Inje University, Seoul, South Korea, inje.ac.kr
9 shared publicationsJungbin Kim
Department of Surgery, College of Medicine, Sanggye Paik Hospital, Inje University, Seoul, South Korea, inje.ac.kr
8 shared publicationsKeunho Yang
Department of Surgery, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea
7 shared publicationsYujin Lee
Department of Surgery, College of Medicine, Sanggye Paik Hospital, Inje University, Seoul, South Korea, inje.ac.kr
7 shared publicationsKyeongmee Park
Department of Pathology, College of Medicine, Sanggye Paik Hospital, Inje University, Seoul, South Korea, medcol.mw
6 shared publicationsInseok Park
Department of Surgery, Sanggye Paik Hospital, Inje University, College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in The Breast Journal
- Vol. 2026 (1) , e3726326
Factors Associated With Preoperative Radiological Tumor Size Underestimation in Clinical T1–2 Breast Cancer Patients
Background: Accurate preoperative tumor size measurement is essential for determining optimal surgical margins in breast cancer patients. Thus, this study aimed to evaluate the factors associated with preoperative radiological tumor underestimation in clinical T (cT) Stage 1–2 breast cancer patients. Methods: We retrospectively reviewed the data of 365 cT1–2 breast cancer patients. Radiological tumor size was defined as the larger dimension on ultrasonography or magnetic resonance imaging. A pathological‐to‐radiological tumor size ratio > 1.2 or a tumor size discrepancy (pathology minus radiology) ≥ 5 mm was considered indicative of radiological underestimation. Preoperative variables, including age, body mass index (BMI), cT stage, maximum standardized uptake value of tumor, molecular subtype, and histologic subtype and grade, were analyzed to identify associated factors. Tumor size discrepancy (pathology minus radiology) was compared across subgroups, and the difference between pathological and radiological tumor size measurements was evaluated in each subgroup. Results: A BMI ≥ 25 kg/m 2 ( p = 0.006) and invasive lobular carcinoma (ILC) histology ( p = 0.030) were associated with a pathological‐to‐radiological tumor size ratio > 1.2. A BMI ≥ 25 kg/m 2 ( p = 0.015), ILC histology ( p = 0.022), and cT stage ( p = 0.027) were associated with a tumor size discrepancy (pathology minus radiology) ≥ 5 mm. Significant differences in tumor size discrepancy between patients with a BMI ≥ 25 kg/m 2 and those with a BMI < 25 kg/m 2 ( p = 0.003) and between patients with an ILC and those with non‐ILC ( p = 0.041) were observed. Bland–Altman analysis showed radiological underestimation in ILCs (4.3 mm). Conclusion: In cT1–2 breast cancer patients, a BMI ≥ 25 kg/m 2 and/or an ILC are predictive of radiological tumor underestimation, warranting supplemental imaging and intraoperative margin assessment.
- 1 January 2026
- Published by Wiley in The Breast Journal
- Vol. 2026 (1) , e3726326
Open AccessFactors Associated With Preoperative Radiological Tumor Size Underestimation in Clinical T1–2 Breast Cancer Patients
Background: Accurate preoperative tumor size measurement is essential for determining optimal surgical margins in breast cancer patients. Thus, this study aimed to evaluate the factors associated with preoperative radiological tumor underestimation in clinical T (cT) Stage 1–2 breast cancer patients. Methods: We retrospectively reviewed the data of 365 cT1–2 breast cancer patients. Radiological tumor size was defined as the larger dimension on ultrasonography or magnetic resonance imaging. A pathological‐to‐radiological tumor size ratio > 1.2 or a tumor size discrepancy (pathology minus radiology) ≥ 5 mm was considered indicative of radiological underestimation. Preoperative variables, including age, body mass index (BMI), cT stage, maximum standardized uptake value of tumor, molecular subtype, and histologic subtype and grade, were analyzed to identify associated factors. Tumor size discrepancy (pathology minus radiology) was compared across subgroups, and the difference between pathological and radiological tumor size measurements was evaluated in each subgroup. Results: A BMI ≥ 25 kg/m 2 ( p = 0.006) and invasive lobular carcinoma (ILC) histology ( p = 0.030) were associated with a pathological‐to‐radiological tumor size ratio > 1.2. A BMI ≥ 25 kg/m 2 ( p = 0.015), ILC histology ( p = 0.022), and cT stage ( p = 0.027) were associated with a tumor size discrepancy (pathology minus radiology) ≥ 5 mm. Significant differences in tumor size discrepancy between patients with a BMI ≥ 25 kg/m 2 and those with a BMI < 25 kg/m 2 ( p = 0.003) and between patients with an ILC and those with non‐ILC ( p = 0.041) were observed. Bland–Altman analysis showed radiological underestimation in ILCs (4.3 mm). Conclusion: In cT1–2 breast cancer patients, a BMI ≥ 25 kg/m 2 and/or an ILC are predictive of radiological tumor underestimation, warranting supplemental imaging and intraoperative margin assessment.
- Open Access
- 19 April 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 310, 113983
The effect of menopausal hormone therapy on thyroid cancer survivors from the National Health Insurance Database in South Korea cohort
- 19 April 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 310, 113983
Open AccessThe effect of menopausal hormone therapy on thyroid cancer survivors from the National Health Insurance Database in South Korea cohort
- Open Access
- 21 December 2023
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (1) , 1-11
Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea–based cohort study
Although many physicians have been concerned that the menopausal hormones used currently in clinical practice may affect the risk of breast cancer, there are currently few informative updated studies about the associations between menopausal hormone therapy (MHT) and the risk of breast cancer. To evaluate the association between the risk of breast cancer and MHT using the National Health Insurance Database in South Korea (HISK) cohort between 2002 and 2019 retrospectively. Postmenopausal women over 40 years of age from 2003 to 2011 were selected as the subject population and their follow-up data were collected until 2019. We analyzed the risk and mortality of breast cancer according to the type of MHT received, namely, tibolone, combined estrogen plus progestin by manufacturer (CEPM), oral estrogen, combined estrogen plus progestin by physician (CEPP), or topical estrogen. The risk of breast cancer increased in the CEPM group (HR 1.439, 95% CI 1.374–1.507, p-value p-value <0.001). This study suggests that the risk of breast cancer is increased by drugs in the CEPM group but not by tibolone, oral estrogen, CEPP, or topical estrogen. The mortality rate from breast cancer is lower with MHT (tibolone, CEPM, oral estrogen) than without MHT.
- 21 December 2023
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (1) , 1-11
Open AccessBreast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea–based cohort study
Although many physicians have been concerned that the menopausal hormones used currently in clinical practice may affect the risk of breast cancer, there are currently few informative updated studies about the associations between menopausal hormone therapy (MHT) and the risk of breast cancer. To evaluate the association between the risk of breast cancer and MHT using the National Health Insurance Database in South Korea (HISK) cohort between 2002 and 2019 retrospectively. Postmenopausal women over 40 years of age from 2003 to 2011 were selected as the subject population and their follow-up data were collected until 2019. We analyzed the risk and mortality of breast cancer according to the type of MHT received, namely, tibolone, combined estrogen plus progestin by manufacturer (CEPM), oral estrogen, combined estrogen plus progestin by physician (CEPP), or topical estrogen. The risk of breast cancer increased in the CEPM group (HR 1.439, 95% CI 1.374–1.507, p-value p-value <0.001). This study suggests that the risk of breast cancer is increased by drugs in the CEPM group but not by tibolone, oral estrogen, CEPP, or topical estrogen. The mortality rate from breast cancer is lower with MHT (tibolone, CEPM, oral estrogen) than without MHT.
- Open Access
- 5 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Association between breast diseases and symptomatic uterine fibroids by using South Korean National Health Insurance database
Both the uterus and breasts have sex hormone dependence, yet there are few studies on the association between breast disease and uterine fibroids (UFs). The purpose of this study was to investigate the incidence of benign breast disease (BBD), carcinoma in situ (CIS), and breast cancer (BC) in women treated for UFs compared to women who were not treated for UFs. This retrospective cohort study used national health insurance data from January 1st, 2011, to December 31st, 2020. We selected women between 20 and 50 years old who (1) were treated for UFs (UF group) or (2) visited medical institutions for personal health screening tests without UFs (control group). We analyzed independent variables such as age, socioeconomic status (SES), region, Charlson comorbidity index (CCI), delivery status, menopausal status, menopausal hormone therapy (MHT), endometriosis, hypertension (HTN), diabetes mellitus (DM), and dyslipidemia based on the first date of uterine myomectomy in the UF group and the first visiting date for health screening in the non-UF group. There were 190,583 and 439,940 participants in the UF and control groups, respectively. Compared with those of the control group, the RRs of BBD, CIS, and BC were increased in the UF group. The hazard ratios (HRs) of BBD, CIS, and BC in the UF group were 1.335 (95% confidence interval (CI) 1.299–1.372), 1.796 (95% CI 1.542–2.092), and 1.3 (95% CI 1.198–1.41), respectively. When we analyzed the risk of BC according to age at inclusion, UFs group had the increased risk of BCs in all age groups in comparison with control group. Women with low SES (HR 0.514, 95% CI 0.36–0.734) and living in rural areas (HR 0.889, 95% CI 0.822–0.962) had a lower risk of BC. Our study showed that women with UFs had a higher risk of BBD, CIS, and BC than those without UFs. This result suggests that women with UFs should be more conscious of BC than those without UFs. Therefore, doctors should consider recommending regular breast self-exams, mammography, or ultrasound for the early detection of BC in women with UFs.
- 5 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Open AccessAssociation between breast diseases and symptomatic uterine fibroids by using South Korean National Health Insurance database
Both the uterus and breasts have sex hormone dependence, yet there are few studies on the association between breast disease and uterine fibroids (UFs). The purpose of this study was to investigate the incidence of benign breast disease (BBD), carcinoma in situ (CIS), and breast cancer (BC) in women treated for UFs compared to women who were not treated for UFs. This retrospective cohort study used national health insurance data from January 1st, 2011, to December 31st, 2020. We selected women between 20 and 50 years old who (1) were treated for UFs (UF group) or (2) visited medical institutions for personal health screening tests without UFs (control group). We analyzed independent variables such as age, socioeconomic status (SES), region, Charlson comorbidity index (CCI), delivery status, menopausal status, menopausal hormone therapy (MHT), endometriosis, hypertension (HTN), diabetes mellitus (DM), and dyslipidemia based on the first date of uterine myomectomy in the UF group and the first visiting date for health screening in the non-UF group. There were 190,583 and 439,940 participants in the UF and control groups, respectively. Compared with those of the control group, the RRs of BBD, CIS, and BC were increased in the UF group. The hazard ratios (HRs) of BBD, CIS, and BC in the UF group were 1.335 (95% confidence interval (CI) 1.299–1.372), 1.796 (95% CI 1.542–2.092), and 1.3 (95% CI 1.198–1.41), respectively. When we analyzed the risk of BC according to age at inclusion, UFs group had the increased risk of BCs in all age groups in comparison with control group. Women with low SES (HR 0.514, 95% CI 0.36–0.734) and living in rural areas (HR 0.889, 95% CI 0.822–0.962) had a lower risk of BC. Our study showed that women with UFs had a higher risk of BBD, CIS, and BC than those without UFs. This result suggests that women with UFs should be more conscious of BC than those without UFs. Therefore, doctors should consider recommending regular breast self-exams, mammography, or ultrasound for the early detection of BC in women with UFs.
- Open Access
- 22 July 2022
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 83 (6) , 1385-1393
Imaging Findings of Metaplastic Breast Carcinoma with Chondroid Differentiation: A Case Reports
김지영, et al. J Korean Soc Radiol. 2022 Jul;83:e62. https://doi.org/10.3348/jksr.2022.0019
- 22 July 2022
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 83 (6) , 1385-1393
Open AccessImaging Findings of Metaplastic Breast Carcinoma with Chondroid Differentiation: A Case Reports
김지영, et al. J Korean Soc Radiol. 2022 Jul;83:e62. https://doi.org/10.3348/jksr.2022.0019
- 8 June 2022
- Published by Korean Breast Cancer Society in Journal of Breast Disease
- Vol. 10 (1) , 40-45
Clinicopatholgic Characteristics to the Relapse on Ductal Carcinoma In Situ: Ki-67 Index as the Most Influential Prognostic Factor
- 8 June 2022
- Published by Korean Breast Cancer Society in Journal of Breast Disease
- Vol. 10 (1) , 40-45
Clinicopatholgic Characteristics to the Relapse on Ductal Carcinoma In Situ: Ki-67 Index as the Most Influential Prognostic Factor
- 8 June 2022
- Published by Korean Breast Cancer Society in Journal of Breast Disease
- Vol. 10 (1) , 46-52
Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer
Purpose: The luminal subtype of breast cancer has heterogeneous biological characteristics with respect to the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and Ki-67. We analyzed luminal B breast cancer subcategorized by PR expression and identified clinically relevant prognostic factors.Methods: We collected the clinical and pathologic data of 247 breast cancer patients (stage 1-4) who were diagnosed with luminal B subtype, defined as ER- and/or PR-positive and/or HER2-positive and with a high Ki-67 proliferation index (>14%). We classified them into PR intact and PR low groups according to PR expression pattern. We also analyzed the clinical and pathological data of each group, including age at diagnosis, tumor size, node metastasis, breast and axillary operative method, margin involvement, tumor-node-metastasis (TNM) stage, histological grade, nuclear grade, number of tumors, and expression of ER, PR, Ki-67, and Bcl-2; evaluated recurrence or metastatic characteristics; and analyzed disease-free survival (DFS) and overall survival (OS) in both groups.Results: Among the 247 luminal B breast cancer patients (stage 1-4), 141 were classified into the PR intact group (57.1%) and 106 into the PR low group (42.9%). The PR low group was associated with age >50 years (p=0.001), low Bcl-2 expression (p<0.001), and high proportion of mastectomies (p<0.001). DFS and OS were significantly lower in the PR low group (p=0.025 and 0.024, respectively).Conclusion: This study showed that decreased in PR expression (PR low group) in luminal B breast cancer was related to poor prognosis compared to normal PR expression (PR intact group).
- 8 June 2022
- Published by Korean Breast Cancer Society in Journal of Breast Disease
- Vol. 10 (1) , 46-52
Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer
Purpose: The luminal subtype of breast cancer has heterogeneous biological characteristics with respect to the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and Ki-67. We analyzed luminal B breast cancer subcategorized by PR expression and identified clinically relevant prognostic factors.Methods: We collected the clinical and pathologic data of 247 breast cancer patients (stage 1-4) who were diagnosed with luminal B subtype, defined as ER- and/or PR-positive and/or HER2-positive and with a high Ki-67 proliferation index (>14%). We classified them into PR intact and PR low groups according to PR expression pattern. We also analyzed the clinical and pathological data of each group, including age at diagnosis, tumor size, node metastasis, breast and axillary operative method, margin involvement, tumor-node-metastasis (TNM) stage, histological grade, nuclear grade, number of tumors, and expression of ER, PR, Ki-67, and Bcl-2; evaluated recurrence or metastatic characteristics; and analyzed disease-free survival (DFS) and overall survival (OS) in both groups.Results: Among the 247 luminal B breast cancer patients (stage 1-4), 141 were classified into the PR intact group (57.1%) and 106 into the PR low group (42.9%). The PR low group was associated with age >50 years (p=0.001), low Bcl-2 expression (p<0.001), and high proportion of mastectomies (p<0.001). DFS and OS were significantly lower in the PR low group (p=0.025 and 0.024, respectively).Conclusion: This study showed that decreased in PR expression (PR low group) in luminal B breast cancer was related to poor prognosis compared to normal PR expression (PR intact group).
- Open Access
- 2 June 2021
- Published by Korean Breast Cancer Society in Journal of Breast Disease
- Vol. 9 (1) , 1-9
Characteristics of HER2-Positive Breast Cancer according to HER2 2+/ Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center
- 2 June 2021
- Published by Korean Breast Cancer Society in Journal of Breast Disease
- Vol. 9 (1) , 1-9
Open AccessCharacteristics of HER2-Positive Breast Cancer according to HER2 2+/ Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center
- Open Access
- 1 January 2021
- Published by Korean Breast Cancer Society in Journal of Breast Cancer
- Vol. 24 (6) , 569-577
A Randomized Controlled Trial for Doing vs. Omitting Intraoperative Frozen Section Biopsy for Resection Margin Status in Selected Patients Undergoing Breast-Conserving Surgery (OFF-MAP Trial)
Yoo TK, et al. J Breast Cancer. 2021 Dec;24(6):569-577. https://doi.org/10.4048/jbc.2021.24.e51
- 1 January 2021
- Published by Korean Breast Cancer Society in Journal of Breast Cancer
- Vol. 24 (6) , 569-577
Open AccessA Randomized Controlled Trial for Doing vs. Omitting Intraoperative Frozen Section Biopsy for Resection Margin Status in Selected Patients Undergoing Breast-Conserving Surgery (OFF-MAP Trial)
Yoo TK, et al. J Breast Cancer. 2021 Dec;24(6):569-577. https://doi.org/10.4048/jbc.2021.24.e51
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Breast Cancer
- Vol. 24 (2) , 164-174
Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
Ahn SG, et al. J Breast Cancer. 2021 Apr;24(2):164-174. https://doi.org/10.4048/jbc.2021.24.e17
- 1 January 2021
- Published by XMLink in Journal of Breast Cancer
- Vol. 24 (2) , 164-174
Open AccessClinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
Ahn SG, et al. J Breast Cancer. 2021 Apr;24(2):164-174. https://doi.org/10.4048/jbc.2021.24.e17